Skip To Main Content
Zin Mar Myint on Muck Rack

Zin Mar Myint

As seen in: Medium, arXiv, ONCOLOGY journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Zin Mar

Contact Zin Mar, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Belzutifan Regimen Boosts Responses, PFS in Clear Cell RCC

|
By Tony Berberabe Verified, Sabrina Serani Verified, Zin Mar Myint
| ONCOLOGY journal Verified
Combining belzutifan (Welireg) with lenvatinib (Lenvima) in the phase 3 LITESPARK-011 trial (NCT04586231) improved the objective response rate (ORR) and progression-free survival (PFS) compared with cabozantinib (Cabometyx) among those with advanced clear cell renal cell carcinoma (RCC) after prior immune checkpoint inhibitor therapy, according to a presentation at the 2026 ASCO Genitourinary Cancers Symposium.1 The first interim analysis (cutoff date June 26, 2024) and second interim...
Open in Who Shared View Duplicates (3) Issue with article?

Zin Myint, MD | Authors | CancerNetwork

|
By Zin Mar Myint
| ONCOLOGY journal Verified
Articles by Zin Myint, MD The phase 2 study aimed to compare the safety of pembrolizumab and radiation with or without olaparib in this high-risk population.
Open in Who Shared Issue with article?

Examining Pembrolizumab Combo Safety in High-Risk Prostate Cancer

|
By Zin Mar Myint, Antonio Ocejo, Courtney Flaherty Verified
| ONCOLOGY journal Verified
In a conversation with CancerNetwork®, Zin Myint, MD, associate professor of Internal Medicine specializing in genitourinary malignancies at the Markey Cancer Center of the University of Kentucky, discussed the background behind a presentation she gave at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, which compared the safety outcomes of pembrolizumab (Keytruda) and radiation with or without olaparib (Lynparza) among patients with high-risk prostate...
Open in Who Shared Issue with article?
See all 5 articles